The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Oral mucositis: the hidden side of cancer therapy
Open accessAbstract
Inflammation response of epithelial mucosa to chemo- radiotherapy cytotoxic effects leads to mucositis, a painful side effect of antineoplastic treatments. About 40% of the patients treated with chemotherapy develop mucositis; this percentage rises to about 90% for head and neck cancer patients (HNC) treated with both chemo- and radiotherapy. 19% of the latter will be hospitalized and will experience a delay in antineoplastic treatment for high-grade mucositis management, resulting in a reduction of the quality of life, a worse prognosis and an increase in patient management costs. Currently, several interventions and prevention guidelines are available, but their effectiveness is uncertain. This review comprehensively describes mucositis, debating the impact of standard chemo-radiotherapy and targeted therapy on mucositis development and pointing out the limits and the benefits of current mucositis treatment strategies and assessment guidelines. Moreover, the review critically examines the feasibility of the existing biomarkers to predict patient risk of developing oral mucositis and their role in early diagnosis. Despite the expression levels of some proteins involved in the inflammation response, such as TNF-α or IL-1β, partially correlate with mucositis process, their presence does not exclude others mucositis-independent inflammation events. This strongly suggests the need to discover biomarkers that specifically feature mucositis process development. Non-coding RNAs might hold this potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Bonner, J. A., Harari, P. M., Giralt, J., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Baselga, J., Spencer, S. A., Zhu, J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70311-0 · Cited by 1,978
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 2×
“Oral mucositis, specifically stomatitis characterized by aphthous ulcer, occurs in very few patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6) [50, 51], used as first- or second-line treatment for hormone positive/HER2 negative metastatic breast cancer.”
BackgroundSonis, S. T. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1318 · Cited by 1,361
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Elad, S., Cheng, K. K. F., Lalla, R. V., Yarom, N., Hong, C., Logan, R. M., Bowen, J., Gibson, R., Saunders, D. P., Zadik, Y., et al. (2020) · Cancer · doi:10.1002/cncr.33100 · Cited by 1,336
Trotti, A., Bellm, L. A., Epstein, J. B., Frame, D., Fuchs, H. J., Gwede, C. K., Komaroff, E., Nalysnyk, L., & Zilberberg, M. D. (2003) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00404-8 · Cited by 1,211
Cited by
Mechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
[Retracted] Quercetin Prevents Radiation‐Induced Oral Mucositis by Upregulating BMI‐1
Zhang, J., Hong, Y., Liuyang, Z., Li, H., Jiang, Z., Tao, J., Liu, H., Xie, A., Feng, Y., Dong, X., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2231680 · Cited by 28
Retracted
Metadata
- Authors
- Pulito, C., Cristaudo, A., Porta, C. L., Zapperi, S., Blandino, G., Morrone, A., & Strano, S.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2020-10-07
- Volume
- 39
- Issue
- 1
- Pages
- 210-210
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W3092643048
- Cited by
- 468
- References
- 104
- FWCI
- 21.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral mucositis: the hidden side of cancer therapy. https://app.cochat.ai/papers/10.1186/s13046-020-01715-7
- The paper
- Pulito, C., Cristaudo, A., Porta, C. L., Zapperi, S., Blandino, G., Morrone, A., & Strano, S. (2020). Oral mucositis: the hidden side of cancer therapy. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-020-01715-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.